Synthetic Biologics, Inc (SYN)
(Delayed Data from AMEX)
$0.64 USD
+0.04 (5.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.64 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Theriva Biologics, Inc. [SYN]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Biologics Announces the Enrollment of First Two Patients in IBS-C Phase 2B Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Biologics Reduces 33% of Workforce; Raising 2019 EPS Estimate
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Biologics Announces Positive End-of-Phase 2 FDA Meeting for Ribaxamase
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Biologics 3Q18 Results; Program Updates and Pipeline Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for SYN
Provider: ValuEngine, Inc
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Global Investment Conference: Synthetic Biologics and Cedars-Sinai Agreement for SYN-010
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
We are Suspending Coverage on the following companies due to analyst transition
Provider: Griffin Securities, Inc.
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Executes 1-for-35 Reverse Stock Split; Updating Model
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Biologics Reports 2Q18 Results; Exploring Partnerships
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Gut Check: Synthetic Biologics Announces Reverse Stock Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 10.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Finally a Path Forward; Initiating Coverage With a Buy Rating and $1 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Price: 50.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 50.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage to better allocate resources within our coverage universe
Provider: H.C. Wainwright & Co., Inc.
Price: 10.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 50.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
CDC May Weigh In on an Important Issue Is Dysbiosis a Medical Condition?
Provider: Griffin Securities, Inc.
Analyst: MARKEY K
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00
Company: Theriva Biologics, Inc.
Industry: Medical - Biomedical and Genetics
Price: 25.00